Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder

Hesse, Swen; Müller, Ulrich; Lincke, Thomas; Barthel, Henryk; Villmann, Thomas; Angermeyer, Matthias C.; Sabri, Osama; Stengler‐Wenzke, Katarina

doi:10.1016/j.pscychresns.2005.07.002

Cited by 138 publications

(89 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, there were considerable differences in severity of OCD among the patient groups as well. On the other hand, the results of the present study are confirmed by three recently published b-CIT and PET studies with untreated OCD patients: Hesse et al (2005), Reimold et al (2007) and Zitterl et al (2007) found significant negative associations between thalamic-hypothalamic SERT binding and obsessive-compulsive scores (Table 2).…”

Section: Discussionsupporting

confidence: 89%

“…Conversely, four further studies revealed reduced SERT availability: Stengler-Wenzke et al (2004) in the midbrain and brainstem and a trend in the thalamic-hypothalamic area, Hesse et al (2005) in the thalamus-hypothalamus, midbrain and brainstem, Reimold et al (2007) in the thalamus and midbrain, and Zitterl et al (2007) in the thalamushypothalamus using an independent sample ( Table 2). The reasons for these differing results lie presumably in the inclusion of heterogeneous groups of OCD patients in most of the previous studies and, furthermore, in differences in ROIs, in methodologies and sample sizes.…”

Section: Discussionmentioning

confidence: 98%

“…The SPECT acquisition time of 4 h post injection used in the present study and in the studies by van der Wee et al (2004) and Zitterl et al (2007) differed from several previous studies, where imaging was performed at 20 or 24 h post injection (Pogarell et al, 2003;Stengler-Wenzke et al, 2004, 2006Hesse et al, 2005). Kinetic studies of b-CIT uptake in SERT-rich brain areas showed a peak in tracer uptake in the thalamus-hypothalamus at 4 h post injection, followed by stable uptake up to 10 h, and a slow decrease up to 24 h post injection.…”

Section: Spect Imaging and Data Analysismentioning

confidence: 90%

“…To the authors' knowledge, there have been seven studies investigating human serotonin transporters (SERT) availability in untreated OCD patients published to date: two PET studies and five b-CIT SPECT studies (Simpson et al, 2003;van der Wee et al, 2004;Pogarell et al, 2003;StenglerWenzke et al, 2004;Hesse et al, 2005;Reimold et al, 2007;Zitterl et al, 2007). The authors are not aware of any studies examining SERT availability in treated OCD patients with the exception of a pilot study of Stengler-Wenzke et al (2006), who treated five OCD patients with citalopram.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Changes in Thalamus–Hypothalamus Serotonin Transporter Availability during Clomipramine Administration in Patients with Obsessive–Compulsive Disorder

Zitterl

Aigner

Stompe

et al. 2008

Neuropsychopharmacol

View full text Add to dashboard Cite

To the authors' knowledge there is as of yet no study demonstrating in vivo alterations in human serotonin transporters (SERT) during clomipramine treatment in patients with obsessive-compulsive disorder. The only study in which SERT binding has been investigated in obsessive-compulsive disorder (OCD) patients before and after treatment is a small pilot study by Stengler-Wenzke et al (2006), who treated five OCD patients with citalopram. In the study at hand, we measured transporter availability in the thalamus-hypothalamus with [ 123 I] b-CIT single photon emission computed tomography (SPECT) in 24 patients with DSM-IV OCD. All patients displayed prominent behavioral checking compulsions (OC-checkers). At baseline and upon medication after 12 weeks of treatment with clomipramine (150 mg daily) 24 non-depressed OC-checkers underwent a SPECT measurement of brain SERT availability using [ 123 I]-2b-carbomethoxy-3b-(4-iodophenyl)tropane. For quantification of brain serotonin transporter availability, a ratio of specific to nondisplaceable [ 123 I] b-CIT brain binding was used (BP ND ¼ (thalamus and hypothalamusÀcerebellum)/cerebellum). The SERT availability was compared between baseline and after treatment and correlated with severity of OC symptomatology and treatment response as assessed with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). After treatment with clomipramine patients showed a 48% reduced brain serotonin transporter availability in the thalamus-hypothalamus, as compared with values at baseline (0.72±0.12 vs 1.39±0.18, po0.001). Correlations between brain SERT availability and OC symptomatology (Y-BOCS scores) revealed significantly negative associations both at baseline and after treatment (r ¼ À0.46; po0.05 and r ¼ À0.53; po0.01 respectively). These data suggest that the SERT availability values could be considered a biological indicator of disease severity. Moreover, in search of predictors we found that higher pretreatment SERT availability significantly predicted better treatment response 12 weeks later (B ¼ 14.145 ± 4.514; t ¼ 3.133; p ¼ 0.005). These results provide further support for an important role of alterations in serotonergic neurons in the pathophysiology of OCD.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 98%

Section: Spect Imaging and Data Analysismentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in Thalamus–Hypothalamus Serotonin Transporter Availability during Clomipramine Administration in Patients with Obsessive–Compulsive Disorder

Zitterl

Aigner

Stompe

et al. 2008

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Dysfunction of brain dopamine (DA) systems, particularly the D2-like superfamily of DA receptors, has been associated with these conditions (Cross et al, 1981;Guttman and Seeman, 1985;Volkow et al, 1993;Hesse et al, 2005). Thus, sex differences in the course and treatment of these disorders may be mediated by differences in dopaminergic function in brain areas affected by these disorders, including striatal regions (eg Munro et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Effect of Menstrual Cycle Phase on Dopamine D2 Receptor Availability in Female Cynomolgus Monkeys

Czoty

Riddick

Gage

et al. 2008

Neuropsychopharmacol

View full text Add to dashboard Cite

Sex differences have been reported in a variety of affective and neurodegenerative disorders that involve dysfunctional dopamine (DA) neurotransmission. In addition, there is evidence for differences in sensitivity to the abuse-related effects of psychostimulants across the menstrual cycle which may result from effects of ovarian hormones on DA function. The goal of the present study was to extend previous work examining menstrual cycle-related changes in DA D2 receptor availability in humans to drug-naive female cynomolgus monkeys (n ¼ 7) using the selective D2-like receptor ligand [ 18 F]fluoroclebopride (FCP) and a high-resolution microPET P4 scanner. Menstrual cycle phase was characterized by daily vaginal swabs and measurements of serum progesterone levels. PET studies were conducted once during the luteal phase and once during the follicular phase. Regions of interest in the caudate nucleus, putamen, and cerebellum were defined on coregistered MRIs. Distribution volumes were calculated for FCP in each structure and the distribution volume ratio (DVR) for both brain regions relative to the cerebellum was used as a measure of D2 receptor availability. FCP DVRs were significantly higher in the luteal phase compared to the follicular phase in both the caudate nucleus (11.7% difference, p ¼ 0.02) and putamen (11.6% difference, p ¼ 0.03). These findings extend earlier work in humans and suggest that changes in DA receptor availability may be involved in the variation in symptoms of various neuropsychiatric disorders across the menstrual cycle, including differences in sensitivity to the abuse-related effects of stimulants.

show abstract

Brain Regional α-[¹¹C]Methyl-L-Tryptophan Trapping in Medication-Free Patients With Obsessive-Compulsive Disorder

Berney

Leyton

Gravel

et al. 2011

Arch Gen Psychiatry

View full text Add to dashboard Cite

show abstract

Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder

Cited by 138 publications

References 40 publications

Changes in Thalamus–Hypothalamus Serotonin Transporter Availability during Clomipramine Administration in Patients with Obsessive–Compulsive Disorder

Changes in Thalamus–Hypothalamus Serotonin Transporter Availability during Clomipramine Administration in Patients with Obsessive–Compulsive Disorder

Effect of Menstrual Cycle Phase on Dopamine D2 Receptor Availability in Female Cynomolgus Monkeys

Brain Regional α-[¹¹C]Methyl-L-Tryptophan Trapping in Medication-Free Patients With Obsessive-Compulsive Disorder

Contact Info

Product

Resources

About

Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder

Cited by 138 publications

References 40 publications

Changes in Thalamus–Hypothalamus Serotonin Transporter Availability during Clomipramine Administration in Patients with Obsessive–Compulsive Disorder

Changes in Thalamus–Hypothalamus Serotonin Transporter Availability during Clomipramine Administration in Patients with Obsessive–Compulsive Disorder

Effect of Menstrual Cycle Phase on Dopamine D2 Receptor Availability in Female Cynomolgus Monkeys

Brain Regional α-[11C]Methyl-L-Tryptophan Trapping in Medication-Free Patients With Obsessive-Compulsive Disorder

Contact Info

Product

Resources

About

Brain Regional α-[¹¹C]Methyl-L-Tryptophan Trapping in Medication-Free Patients With Obsessive-Compulsive Disorder